



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Pantoprazole (Standard)

Cat. No.:	HY-17507R
CAS No.:	102625-70-7
Molecular Formula:	C ₁₆ H ₁₅ F ₂ N ₃ O ₄ S
Molecular Weight:	383.37
Target:	Bacterial; Proton Pump; Autophagy; Apoptosis
Pathway:	Anti-infection; Membrane Transporter/Ion Channel; Autophagy; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Pantoprazole (Standard) is the analytical standard of Pantoprazole. This product is intended for research and analytical applications. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) ^[1] . Pantoprazole, a substituted benzimidazole, is a potent H ⁺ /K ⁺ -ATPase inhibitor with an IC ₅₀ of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) ^{[3][4]} .
IC₅₀ & Target	proton pump

REFERENCES

- [1]. Krupa J Patel, et al. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. *Clin Cancer Res.* 2013 Dec 15;19(24):6766-76.
- [2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. *J Enzyme Inhib Med Chem.* 2020 Dec;35(1):1322-1330.
- [3]. W Beil, et al. Pantoprazole: a novel H⁺/K⁺-ATPase inhibitor with an improved pH stability. *Eur J Pharmacol.* 1992 Aug 6;218(2-3):265-71.
- [4]. K Takeuchi, et al. Effects of pantoprazole, a novel H⁺/K⁺-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. *J Gastroenterol Hepatol.* 1999 Mar;14(3):251-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA